Cargando…

Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience

Purpose: Metastatic pancreatic adenocarcinoma has a very poor prognosis. Although irinotecan, oxaliplatin and leucovorin-modulated fluorouracil (FOLFIRINOX) significantly increases survival in advanced pancreatic cancer, compared to employing only gemcitabine (GEM), toxicities have tempered enthusia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cavanna, Luigi, Stroppa, Elisa Maria, Citterio, Chiara, Mordenti, Patrizia, Di Nunzio, Camilla, Peveri, Silvia, Orlandi, Elena, Vecchia, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498392/ https://www.ncbi.nlm.nih.gov/pubmed/31118666 http://dx.doi.org/10.2147/OTT.S200754

Ejemplares similares

Metastatic Breast Cancer to the Gastrointestinal Tract: Report of Five Cases and Review of the Literature
por: Ambroggi, Massimo, et al.
Publicado: (2012)

Impact of the COVID-19 pandemic on the oncologic activities (diagnosis, treatment, clinical trials enrollment) of a general hospital in a district with high prevalence of SARS-COV-2 in Italy
por: Ambroggi, Massimo, et al.
Publicado: (2022)

Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis
por: Citterio, Chiara, et al.
Publicado: (2018)

Ultrasound guidance reduces pneumothorax rate and improves safety of thoracentesis in malignant pleural effusion: report on 445 consecutive patients with advanced cancer
por: Cavanna, Luigi, et al.
Publicado: (2014)

Safety and Efficacy of Modified FOLFIRINOX in Unresectable or Metastatic Gallbladder Cancer: A Phase II Pilot Study
por: Sharma, Atul, et al.
Publicado: (2021)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Central venous catheterization in cancer patients with severe thrombocytopenia: Ultrasound-guide improves safety avoiding prophylactic platelet transfusion
por: Cavanna, Luigi, et al.
Publicado: (2020)

FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer
por: Adenis, Antoine, et al.
Publicado: (2021)

Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy)
por: Stroppa, Elisa Maria, et al.
Publicado: (2020)

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
por: Hosein, Peter J, et al.
Publicado: (2012)

The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis
por: Zhang, Beilei, et al.
Publicado: (2021)

Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis
por: Cavanna, Luigi, et al.
Publicado: (2019)

Feasibility and Utility of Incorporating Patient-Reported Outcomes into Surveillance Strategies for Advanced Lung Cancer
por: Cavanna, Luigi, et al.
Publicado: (2020)

A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer
por: Yoshida, Kensaku, et al.
Publicado: (2017)

Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX
por: Shirasu, Hiromichi, et al.
Publicado: (2018)

Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis
por: Chae, Heejung, et al.
Publicado: (2020)

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
por: Péron, Julien, et al.
Publicado: (2016)

Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second‐line treatment regimen for unresectable pancreatic cancer: A real‐world analysis
por: Tezuka, Shun, et al.
Publicado: (2021)

Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
por: Vogl, Ursula M., et al.
Publicado: (2019)

A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer
por: Chen, Kuei-Ting, et al.
Publicado: (2023)

Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer
por: Kunzmann, Volker, et al.
Publicado: (2014)

Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX?
por: Fernandes, Gustavo dos Santos, et al.
Publicado: (2019)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX
por: Kim, Jinkook, et al.
Publicado: (2021)

FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Cancer: A Single Centre Cohort Study
por: Rombouts, SJ, et al.
Publicado: (2016)

Clinical Outcomes of Conversion Surgery after FOLFIRINOX in Patients with Unresectable Advanced Pancreatic Cancer: A Retrospective Cohort Study at a Single Center
por: Mita, Naoki, et al.
Publicado: (2021)

Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
por: Mita, Naoki, et al.
Publicado: (2019)

Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer
por: Hino, Kaori, et al.
Publicado: (2022)

Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution
por: Quan, Qi, et al.
Publicado: (2020)

Hepatic Arterial Infusion Chemotherapy With Folfirinox or Oxaliplatin Alone in Metastatic Colorectal Cancer
por: Randrian, Violaine, et al.
Publicado: (2022)

Ultrasound-guided Central Venous Catheterization for Home Parenteral Nutrition and Hydratation in Advanced Incurable Cancer Patients: Results of A Prospective Observational Study
por: Cavanna, Luigi, et al.
Publicado: (2011)

Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
por: Di Costanzo, Francesco, et al.
Publicado: (2023)

Non-Hodgkin Lymphoma Developed Shortly after mRNA COVID-19 Vaccination: Report of a Case and Review of the Literature
por: Cavanna, Luigi, et al.
Publicado: (2023)

Malignant pleural mesothelioma metastatic to the submandibular salivary gland, simulating glandular hypertrophy, diagnosed by fine-needle aspiration biopsy: a case report and literature review
por: Ambroggi, Massimo, et al.
Publicado: (2014)

Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer
por: Mie, Takafumi, et al.
Publicado: (2023)

Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer
por: Sadaka, Shiori, et al.
Publicado: (2022)

Bedside Peripheral Ultrasound-Guided Vascular Access in 253 Patients Hospitalized With COVID-19 Pneumonia: A Retrospective Italian Study
por: Oleari, Francesco, et al.
Publicado: (2022)

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Okusaka, Takuji, et al.
Publicado: (2014)

Results of a single-arm pilot study of (32)P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy
por: Ross, P.J., et al.
Publicado: (2021)

Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study
por: Kim, Jung Hoon, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o7r2dls0sh5l7udaf4hm8rs29d